Decisive Diagnostics is open to various mutually beneficial forms of collaboration, including co-development of products in our pipeline, out-licensing and fee-based services.  Please contact us to find out more about our varied portfolio of patents and pending patents as well as opportunities to license our human cell lines.

Patent Portfolio

  • Bladder Cancer
  • Colon Cancer
  • Human DNA Reference Controls
  • Warfarin Dosing
  • Methods of Identifying Sequence Differences
  • Dual Labeled Nucleotides
  • Antibodies

Cell Lines

  • 24 human cell lines
  • Obtained from properly consented donors
  • Characterized for important drug metabolism genes
  • Appropriate for use in pharmacogenomic assays, aCGH applications, ADME studies, and lab proficiency tests employing genomic DNA
  • Exclusive and non-exclusive licenses available

Comments are closed.